Inditex celebrated a strong showing on the stock market on February fourth. The textile company is the parent company of Zara, Pull & Bear, and Massimo Dutti, among other brands. Inditex shares increased in value by 2.32% on the stock market, thanks to the support of RBC Capital Markets. These analysts have once again included the company among their favorite stocks, while raising the target price they give it by 6%
Breaking stories in market & business news are available with the Born2Invest mobile app. Keep up to date with the latest business stories updated throughout the day.
Taking stock of the situation
Inditex’s shares were among the most bullish on the Spanish stock market on February 4th. The company closed on Monday, February 3rd, at $33,60 (€30,55) per share. On Tuesday, February 4th, the shares hit an intraday high of $34,62 (€31.48). The reason for that is the clear support received from RBC.
It’s no secret that this Canadian investment bank is a fan of the apparel giant founded by Amancio Ortega. Investors are celebrating the fact that RBC has once again included Ortega among its favorite stocks. In particular, it has once again placed its recommendation on the company in ‘top pick’ after lowering it to ‘over return’ (comparable to ‘buy’) last September, after more than a year and a half of ‘favoritism’.
The analysts predict that the “strong performance of comparable sales” of Inditex will continue. They also believe that “the positive effect of a weaker euro on its profits is underestimated.” The company will publish its results for the 2019 fiscal year on March 18th.
As a result, RBC has raised its 12-month price target by 6%, going from $36,43 (€33) per share to $38,64 (€35). This represents a double-digit upward potential for the company’s shares in the short term, giving 14.6% with respect to the closing price.
The Canadian investment bank already pointed out Inditex as its favorite among European textile companies in April 2019, stressing then that “the forecasts in terms of cash flow and margins for the sector” were improving.
More optimism than consensus
However, the Toronto-based company’s forecasts for textiles are much more optimistic than those of the marketplace. Moreover, the consensus of analysts gathered by Bloomberg considers that the owner of Zara no longer has potential on the stock market: it gives it an average 12-month target price of $33,84 (€30,65) per share.
Even so, almost half of these experts (45.2%) advise ‘buying’ Inditex shares. Another 35.5% gave a recommendation to ‘hold’ and the remaining 19.4% opted to ‘sell’.
Time to go all in?
To buy or not to buy? That’s the question. And even more so when the stock starts rising so sharply. In Joan Cabreros (Ecotrader’s Strategy Director) opinion, if you look at the technical analysis, it is time to bet on Inditex. She mentioned this during a commentary on Monday, February 3rd, and invited people to buy if the shares were to exceed $34,40 (€31,16) in value, something that we saw happen the next day on Tuesday, February 4th.
The expert believes that Inditex’s shares will “very probably” revalue in the short term to $37,86 (€34,30), that is, to the historical maximums reached in 2017. This represents a journey of more than 9% from its current levels.
“In the worst case the current correction could seek the old resistance, now support, of $32,01 (€29),” added the technical analyst. Although he bets more that “the increases will be resumed without reaching this environment.”
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in elEconomista.es, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The TopRanked.io Weekly Digest: What’s Hot in Affiliate Marketing [1xBet Affiliate Program]
Wanna discover one weird sports betting niche with plenty of low-hanging fruit just waiting for you to exploit? Then read...
Which Are the Most Important Fintech News from February 2024
Monite secured $6 million in a top-up financing round, bringing its total seed-stage funding to $16 million. The funds will...
Spanish Pharma Listed Companies Reduce Their Profits by 37% in 2023
Of the Spanish pharma listed companies, PharmaMar has suffered the most significant drop in profits due to generic drug competition...
How Much Does Europe Invest in Sustainability
Europe is moving rapidly towards a renewal of the regulatory framework for sustainability , with the obligation for almost 50,000...
The German Medical Cannabis Market Could Be Worth Three Billion
Currently, the German medical cannabis market serves a relatively small part of the population, with approximately 28,000 patients, or less...
Markets6 days ago
Why a Financial Black Swan on the Stock Market Remains a Possibility
Crypto2 weeks ago
With Bitcoin ETFs Behind It, BTC Will Rise to $80,000 – Analyst Says
Biotech4 days ago
Oryzon Cuts Losses by 20.7%, Faes Farma Earns almost 92 Million in 2023
Impact Investing1 week ago
Medical Microinstruments Raises an Impressive Amount of $110 Million